HC Wainwright Has Strong Estimate for Nicox FY2026 Earnings

Nicox SA (OTCMKTS:NICXF) – Equities research analysts at HC Wainwright increased their FY2026 earnings estimates for Nicox in a research report issued to clients and investors on Tuesday, January 6th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn $0.15 per share for the year, up from their previous forecast of $0.12. HC Wainwright also issued estimates for Nicox’s Q4 2026 earnings at $0.11 EPS.

Separately, Zacks Research upgraded shares of Nicox to a “hold” rating in a report on Friday, October 10th. One research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy”.

Nicox Price Performance

Nicox stock opened at $0.30 on Wednesday. The company’s 50-day moving average price is $0.30 and its two-hundred day moving average price is $0.29. Nicox has a 52 week low of $0.25 and a 52 week high of $0.30.

About Nicox

Nicox is a global biopharmaceutical company focused on the research, development and commercialization of innovative treatments for eye diseases. The company’s therapeutic approach centers on nitric oxide–donating compounds and anti-inflammatory agents designed to address glaucoma, ocular surface disorders and allergic eye conditions. With a pipeline spanning pre-clinical to late-stage clinical programs, Nicox aims to bring new modalities to market that target unmet needs in ophthalmology.

The company’s lead commercial product, ZERVIATE® (ciclesonide ophthalmic solution), is indicated for the relief of ocular itching associated with allergic conjunctivitis.